FDA approves hepcidin mimetic for PV - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

  • By

  • Kathryn Wighton

  • August 31, 2026

  • 3 min

Share

  • 1

    Rusfertide (MIMRYLO) received FDA approval for treating erythrocytosis in adults with polycythemia vera.

  • 2

    Polycythemia vera is a chronic blood cancer characterized by elevated hematocrit, increasing the risk of thrombotic events.

  • 3

    The phase 3 VERIFY trial showed that 77% of patients on rusfertide plus standard care achieved a clinical response.

  • 4

    Rusfertide is administered weekly via subcutaneous injection and is designed to control hematocrit and reduce phlebotomy needs.

  • 5

    Common adverse reactions to rusfertide include injection-site reactions (56%) and anemia (16%), with warnings for thrombocytosis and embryo-fetal toxicity.

Original Source(s)

FDA approves hepcidin mimetic for PV

  • by Kathryn Wighton

  • August 31, 2026

Related Content

Does portal writing style contribute to disparities in clinician response?

Message length, punctuation, and clinician greetings were associated with intended clinician response.

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.